
The Quebec Pancreas Cancer Study (QPCS)
The Quebec Pancreas Cancer Study (QPCS) was established as a familial pancreatic cancer registry with a strategy to provide patients with point-of-care hereditary risk assessment and genetic testing. The QPCS has been expanded to include biliary tract cancers and related tumours, such as ampullary cancers and premalignant cystic neoplasms. To pursue hereditary and biomarker discovery studies, the study has an accompanying biospecimen repository with a living biobank of patient-derived tumour models. The QPCS is registered with the Réseau de recherche sur le cancer (RRCancer) and accredited by the Canadian Tumor Repository Network (CTRNet).
The QPCS is embedded within the outpatient medical and surgical oncology clinics at the Cedars Cancer Centre of the McGill University Health Centre. Through this research strategy, the QPCS was a pioneer in bringing routine genetic testing with rapid return of results to cancer patients at the McGill University Health Centre and across Quebec. Over the years, the QPCS has expanded to bring innovative precision health translational and clinical trial opportunities to patients.
How to participate
The QPCS is open to enrollment. ClinicalTrials.gov ID: NCT04104230

Pancreatic Cancer Early Detection and Interception
The goal of this integrated clinical and research program is early detection and interception of precancerous and cancerous changes in the pancreas. The program incorporates the clinical recommendation that individuals at high risk for pancreatic cancer undergo clinical surveillance in a research setting. In 2013, the QPCS was expanded to offer pancreatic cancer surveillance to high-risk individuals in Quebec. The program is the first of its kind in Quebec, the largest in Canada, and a founding site of the Pancreatic Cancer Early Detection (PRECEDE) Consortium (https://precedestudy.org/). PRECEDE is an international, multi-institutional collaborative group working to increase pancreatic cancer survival by improving early detection and prevention.
How to participate
This study is open to enrollment. ClinicalTrials.gov ID: NCT04970056

Biliary Tract Cancer Molecular Profiling Trial
Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers for Better Treatment Selection (COMPASS-B-MUHC) is a prospective molecular profiling trial for patients with advanced biliary tract cancers. Patients enrolled in the study undergo a biopsy before the start of their treatment to molecularly profile their tumour (whole genome and whole transcriptome sequencing). These molecular profiling results are returned to the patients and their oncologists to guide precision therapy treatment decisions. In addition to real-time clinical impacts, the genomic and transcriptomic data as well as longitudinal liquid biopsy biospecimens will be used for discovery studies to improve our understanding of the development and progression of biliary tract cancers.
How to participate
This trial is open to patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer) who have not yet started treatment and who intend on receiving their cancer treatment (including chemotherapy) at the McGill University Health Centre.
ClinicalTrials. gov ID: NCT04318834
For patients receiving cancer treatment at another hospital, they may be eligible for tumour profiling (whole genome and whole transcriptome sequencing) through one of our Marathon of Hope Cancer Centres Network (MOHCCN) projects.